Pipeline Overview

Program
Target
Indications
Discovery
Pre-clinical development
Early phase
Rights
Program: Cemsidomide
Target: IKZF1/3
Multiple Myeloma & Non-Hodgkin’s Lymphoma
Indications Multiple Myeloma & Non-Hodgkin’s Lymphoma
Early phase
Right 1
Program: CFT1946
Target: BRAF V600
V600 Mutant Cancers
Indications V600 Mutant Cancers
Early phase
Right 1
Program: CFT8919*
Target: EGFR L858R
Non-Small Cell Lung Cancer
Indications Non-Small Cell Lung Cancer
Early phase
Right 1 Right 2
Program: Undisclosed
Target: Chromatin Regulating
Various Cancers
Indications Various Cancers
Discovery
Right 1
Program: Undisclosed
Target: Oncogenic Signaling
Various Cancers
Indications Various Cancers
Discovery
Right 1
Program: Undisclosed
Target: Transcription Factor
Various Cancers
Indications Various Cancers
Discovery
Right 1

*Exclusive License and Collaboration Agreement with Betta Pharmaceuticals for the development and commercialization in Greater China

Learn more about our partnerships